Dig Dis Sci. 2025 Oct 9. doi: 10.1007/s10620-025-09431-y. Online ahead of print.
ABSTRACT
Cholestatic liver diseases are a heterogeneous group of disorders characterized by impaired bile formation or flow, leading to bile salt accumulation and progressive liver injury. This term encompasses a broad spectrum of conditions, including genetic disorders, autoimmune biliary diseases, drug-induced liver injury, and mechanical or postsurgical biliary obstruction. Genetic testing has become essential in identifying hereditary cholestasis, particularly useful for conditions without clear etiologies, atypical presentations, or inadequate treatment responses. These diseases often significantly impact patient’s quality of life, manifesting as chronic symptoms such as pruritus, fatigue, and impose substantial burdens on healthcare systems due to chronic management requirements and potential progression to severe complications necessitating liver transplantation. Early-onset cholestatic diseases are typically associated with genetic abnormalities, yet recent advances have revealed that genetic variants also contribute significantly to adult-onset cases. Integration of genetic testing with clinical assessments including biochemical analysis, imaging, detailed family histories, and collaboration with histopathologists and geneticists is vital for accurate diagnosis and optimized patient care. Recognizing underlying genetic causes facilitates personalized management strategies and provides opportunities for innovative therapeutic approaches, including FXR ligands and IBAT inhibitors. Although current data on genotype-phenotype correlations are limited, ongoing genetic discoveries hold promise for improving prognosis prediction and personalized treatment strategies. Consequently, the wider implementation of genetic testing in clinical practice is justified, enhancing disease understanding and patient outcomes.
PMID:41066043 | DOI:10.1007/s10620-025-09431-y
